

Title (en)

THE USE OF ERIOCALYXIN B IN THE MANUFACTURE OF MEDICAMENTS FOR TREATING LEUKEMIA

Title (de)

VERWENDUNG VON ERIOCALYXIN B BEI DER HERSTELLUNG VON MEDIKAMENTEN ZUR BEHANDLUNG VON LEUKÄMIE

Title (fr)

UTILISATION DE L'ERIOCALYXINE B POUR LA FABRICATION DE MEDICAMENTS DESTINES AU TRAITEMENT DE LA LEUCEMIE

Publication

**EP 1952811 A1 20080806 (EN)**

Application

**EP 06791205 A 20061008**

Priority

- CN 2006002623 W 20061008
- CN 200510110089 A 20051107

Abstract (en)

The use of eriocalyxin B in the manufacture of medicaments for treating leukemia, wherein the leukemia include leukemia containing AML1-ETO fusion protein, acute promyelocytic leukemia, acute myelocytic leukemia and lymphocytic leukemia. Eriocalyxin B increases the level of peroxidate and influences the phosphorylation and degradation of I<sup>κ</sup>B± to prevent NF-<sup>κ</sup>B from getting into the nucleus in order to inhibition NF-<sup>κ</sup>B pathway. Eriocalyxin B can decrease the phosphorylation of ERI1/2 and inhibit MAPK pathway. Eriocalyxin B can extend the life span of mice and decrease tumor volume in mice model of C57 leukemia and tumor transplantation.

IPC 8 full level

**A61K 31/352** (2006.01); **A61P 35/02** (2006.01)

CPC (source: EP US)

**A61K 31/352** (2013.01 - EP US); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP)

Cited by

EP3007686A4

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**EP 1952811 A1 20080806**; **EP 1952811 A4 20100922**; CN 100370981 C 20080227; CN 1868468 A 20061129; JP 2009514903 A 20090409; US 2008300299 A1 20081204; WO 2007051390 A1 20070510

DOCDB simple family (application)

**EP 06791205 A 20061008**; CN 200510110089 A 20051107; CN 2006002623 W 20061008; JP 2008539213 A 20061008; US 9291406 A 20061008